Dosing regimen for a selective S1P1 receptor agonist

A method for administering (R)-5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]-propylimino)-3-o-tolyl-thiazolidin-4-one (Compound 1), or a pharmaceutically acceptable salt thereof to a subject in need thereof, wherein, during the an initial treatment phase Compound 1, or a pharmaceutically acceptable salt thereof is administered at a dose which induces desensitization of the heart to acute heart rate reduction, said dose being below the target dose, and at a dosing frequency that sustains desensitization of the heart, until no further acute heart rate reduction occurs, followed by dose up-titration to the target dose of Compound 1, or a pharmaceutically acceptable salt thereof.